Monastrol

别名: (±)-Monastrol

此产品请避光密封保存。

目录号：S8439 Purity: 99.86%

Monastrol ((±)-Monastrol)是一种具有细胞透性的kinesin-5(KIF11)小分子抑制剂，IC50为14μM，kinesin-5(KIF11)可保持半纺锤体的分离状态。

Monastrol Chemical Structure

CAS: 329689-23-8

规格	价格	库存
10mg	1204.01	现货
50mg	4070.85	现货
200mg	12039.31	现货
1g	32678.74	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.86%

99.86

Monastrol相关产品

相关靶点	Kinesin-12	点击展开
相关产品	GSK923295 Ispinesib (SB-715992) SB743921 HCl ARQ 621	点击展开
相关化合物库	激酶抑制剂库血管生成相关化合物库 TGF-beta/Smad信号通路库细胞骨架信号通路化合物库抗心血管疾病化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息(PMID)
C6	Antiproliferative assay	100 uM	24 hrs	Antiproliferative activity against rat C6 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTS assay relative to control	ChEMBL
C6	Cell cycle assay	100 uM	24 hrs	Cell cycle arrest in rat C6 cells assessed as accumulation at G2/M phase at 100 uM after 24 hrs by propidium iodide staining based flow cytometry	ChEMBL
U138MG	Apoptosis assay	200 uM	48 hrs	Induction of apoptosis in human U138MG cells at 200 uM after 48 hrs by Annexin V/propidium iodide staining based flow cytometry	ChEMBL
U138MG	Necrosis assay	200 uM	48 hrs	Induction of necrosis in human U138MG cells at 200 uM after 48 hrs by Annexin V/propidium iodide staining based flow cytometry	ChEMBL
C6	Apoptosis assay	100 uM	48 hrs	Induction of apoptosis in rat C6 cells at 100 uM after 48 hrs by Annexin V/propidium iodide staining based flow cytometry	ChEMBL
U138MG	Function assay	200 uM	24 hrs	Inhibition of EG5 in human U138MG cells assessed as monopolar spindle formation at 200 uM after 24 hrs by Hoechst staining based immunofluorescence microscopic method	ChEMBL
C6	Function assay	100 uM	24 hrs	Inhibition of EG5 in rat C6 cells assessed as monopolar spindle formation at 100 uM after 24 hrs by Hoechst staining based immunofluorescence microscopic method	ChEMBL
C6	Antiproliferative assay	5 to 50 uM	48 hrs	Antiproliferative activity against rat C6 cells at 5 to 50 uM after 48 hrs by Neubauer chamber method	ChEMBL
MCF7	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human MCF7 cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
NCI/ADR-RES	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human NCI/ADR-RES cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
786-0	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human 786-0 cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
HT-29	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human HT-29 cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
UACC62	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human UACC62 cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
PC3	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human PC3 cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
OVCAR3	Antiproliferative assay	25 uM	48 hrs	Antiproliferative activity against human OVCAR3 cells at 25 uM after 48 hrs by sulforhodamine B assay	ChEMBL
KBV1	Antiproliferative assay		72 hrs	Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay in presence of zosuquidar, EC50=45.394μM	20597485
hTERT-HME1	Antiproliferative assay		72 hrs	Antiproliferative activity against human hTERT-HME1 cells after 72 hrs by Alamar blue assay, EC50=45.082μM	20597485
HCT116	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT116 cells after 72 hrs by Alamar blue assay, EC50=24.155μM	20597485
HeLa	Function assay		12 hrs	Inhibition of Eg5 ATPase activity expressed in HeLa cells after 12 hrs, IC50=6.1μM	17587586
HL-60(TB)	Growth inhibition assay		24 hrs	Growth inhibition of human HL-60(TB) cells incubated for 24 hrs by MTT assay, IC50=0.147μM	28667871
MOLT4	Growth inhibition assay		24 hrs	Growth inhibition of human MOLT4 cells incubated for 24 hrs by MTT assay, IC50=0.215μM	28667871
McCoy	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse McCoy cells assessed as decrease in cell viability after 72 hrs by MTT assay, IC50=26.8μM	29908443
MM1S	Antiproliferative assay		72 hrs	Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay, IC50=8.7μM	ChEMBL
HCT116	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay, IC50=9μM	ChEMBL
CCRF-CEM	Growth inhibition assay			Growth inhibition of human CCRF-CEM cells, GI50=31.6μM	21855351
M14	Growth inhibition assay			Growth inhibition of human M14 cells, GI50=25.1μM	21855351
HL-60(TB)	Growth inhibition assay			Growth inhibition of human HL-60(TB) cells, GI50=25.1μM	21855351
KBV1/KB3-1	Function assay			Drug resistant ratio of EC50 for human KBV1 cells overexpressing MDR1 to EC50 for KB3-1 cells, EC50=0.0012μM	20597485
HCT116	Cell cycle assay			Effect on cell cycle progression in human HCT116 cells assessed as increase in phospho-histone H3 by fluorescence microscopy, EC50=1.5μM	18793847
HCT116	Cell cycle assay			Effect on cell cycle progression in human HCT116 cells assessed as mitotic arrest measured by doubling DNA content by fluorescence microscopy, EC50=1.2μM	18793847
K562	Growth inhibition assay			Growth inhibition of human K562 cells, GI50=31.6μM	21855351
MOLT4	Growth inhibition assay			Growth inhibition of human MOLT4 cells, GI50=31.6μM	21855351
SR	Growth inhibition assay			Growth inhibition of human SR cells, GI50=31.6μM	21855351
NCI-H522	Growth inhibition assay			Growth inhibition of human NCI-H522 cells, GI50=31.6μM	21855351
COLO205	Growth inhibition assay			Growth inhibition of human COLO205 cells, GI50=31.6μM	21855351
HCT116	Growth inhibition assay			Growth inhibition of human HCT116 cells, GI50=31.6μM	21855351
KM12	Growth inhibition assay			Growth inhibition of human KM12 cells, GI50=31.6μM	21855351
SF295	Growth inhibition assay			Growth inhibition of human SF295 cells, GI50=31.6μM	21855351
U251	Growth inhibition assay			Growth inhibition of human U251 cells, GI50=31.6μM	21855351
SK-MEL-2	Growth inhibition assay			Growth inhibition of human SK-MEL-2 cells, GI50=31.6μM	21855351
RPMI8266	Growth inhibition assay			Growth inhibition of human RPMI8266 cells, GI50=31.6μM	21855351
NCI-H322M	Growth inhibition assay			Growth inhibition of human NCI-H322M cells, GI50=39.8μM	21855351
HCC2998	Growth inhibition assay			Growth inhibition of human HCC2998 cells, GI50=39.8μM	21855351
HCT15	Growth inhibition assay			Growth inhibition of human HCT15 cells, GI50=39.8μM	21855351
SW620	Growth inhibition assay			Growth inhibition of human SW620 cells, GI50=39.8μM	21855351
SNB75	Growth inhibition assay			Growth inhibition of human SNB75 cells, GI50=39.8μM	21855351
SK-MEL-5	Growth inhibition assay			Growth inhibition of human SK-MEL-5 cells, GI50=39.8μM	21855351
UACC62	Growth inhibition assay			Growth inhibition of human UACC62 cells, GI50=39.8μM	21855351
SN12C	Growth inhibition assay			Growth inhibition of human SN12C cells, GI50=39.8μM	21855351
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
U-2 OS	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	29435139
点击查看更多细胞系数据

生物活性

产品描述

Monastrol ((±)-Monastrol)是一种具有细胞透性的kinesin-5(KIF11)小分子抑制剂，IC50为14μM，kinesin-5(KIF11)可保持半纺锤体的分离状态。

靶点

KIF11(Eg5) ^[4]
(Cell-based assay)

14 μM

体外研究(In Vitro)
体外研究活性	Monastrol并不是通过细胞周期的S期和G2期或中心体复制抑制细胞周期进程。monastrol的有丝分裂阻滞作用快速可逆。它还能在爪蟾卵提取物中抑制双极纺锤体的形成。Monastrol将细胞阻滞在有丝分裂期，但在体外不影响处于有丝分裂间期细胞的微管或是微管聚合^[1]。将交感神经元细胞暴露于monastrol几小时，将会增加轴突数量及生长速率。但时间延长，轴突的总体长度则与对照组无异。感觉神经元同样也有这种轴突生长速率短期升高的效果，然而，进一步延长暴露时间将导致轴突变短，说明感觉神经元细胞对药物的毒性作用更为敏感。但是，细胞整体培养状况比taxol处理组要更为强健，taxol是一种常用于治疗癌症的药物^[2]。在HeLa细胞中，monastrol激活纺锤体检验点，导致有丝分裂受到阻滞，引起凋亡^[3]。
细胞实验	细胞系	BS-C-1 (猴肾脏上皮)细胞
	浓度	100 μM
	孵育时间	4 h
	方法	在胸腺嘧啶脱氧核苷双重阻滞实验中，处于生长对数期的BS-C-1细胞在含2 mM胸苷的正常培养基中培养。然后将细胞置于含24 μM deoxycytidine的培养基中培养9小时。第二次阻滞时，将细胞至于要含2 mM 胸苷的无血清培养基中16小时。最后，将细胞重新置于含24 μM deoxycytidine的培养基中，加入100 μM monastrol或0.1% DMSO。为了检测monastrol和nocodazole的作用是否具有可逆性。将BS-C-1铺于盖玻片上，用含2 μM nocodazole或是100 μM monastrol的正常生长培养基处理4小时，然后将细胞置于正常培养基。在不同的时间节点，将盖玻片进行免疫荧光染色，对处于有丝分裂间期或有丝分裂期的细胞进行计数。
实验图片	检测方法	检测指标	实验图片	PMID
	Growth inhibition assay	Cell viability		26035434
	Western blot	Cyclin B / Survivin		26035434

参考文献
https://pubmed.ncbi.nlm.nih.gov/10973989/ https://pubmed.ncbi.nlm.nih.gov/14983520/ https://pubmed.ncbi.nlm.nih.gov/17041103/ https://pubmed.ncbi.nlm.nih.gov/10542155/ + 展开

参考文献

https://pubmed.ncbi.nlm.nih.gov/10973989/
https://pubmed.ncbi.nlm.nih.gov/14983520/
https://pubmed.ncbi.nlm.nih.gov/17041103/

https://pubmed.ncbi.nlm.nih.gov/10542155/

+ 展开

化学信息&溶解度

分子量	292.35	分子式	C₁₄H₁₆N₂O₃S
CAS号	329689-23-8	SDF	Download Monastrol SDF
Smiles	CCOC(=O)C1=C(NC(=S)NC1C2=CC(=CC=C2)O)C
储存条件(自收到货起)	3年 -20°C(避光) 粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年 -20°C(避光) 粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 58 mg/mL ( (198.39 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 58 mg/mL (198.39 mM)

Water : Insoluble

DMSO : 69 mg/mL ( (236.01 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 15 mg/mL (51.3 mM)

Water : Insoluble

摩尔浓度计算器

体内溶解配方批次：现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂				动物体内配方计算器
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	2.900mg/ml (9.92mM)	以 1 mL 工作液为例,取50μL58mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
澄清溶液	5% DMSO 1 95% Corn oil 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	0.710mg/ml (2.43mM)	以1 mL工作液为例，取50μL 14.2mg/ml的澄清DMSO储备液加到950μL玉米油中，混合均匀。工作液请现配现用！
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):